All In Biotech

Drug Trial Radar · NCT00056407

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,231

Actual

Start

Mar 2003

Primary completion

Jan 2009

Study completion Apr 2009

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 13, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Male only, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.

Conditions

  • Neoplasms, Prostate

Interventions

  • DutasterideDrug

    After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.

  • PlaceboDrug

    After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach)Time frame: Years 1-2, Years 3-4, and Overall (Years 1-4)
  2. Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Modified Crude Rate Approach)Time frame: Years 1-2, Years 3-4, and Overall (Years 1-4)
  3. Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Restricted Crude Rate Approach)Time frame: Years 1-2, Years 3-4, and Overall (Years 1-4)

Locations

932 sites in 42 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Homewood, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Anchorage, Alaska

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Sun City, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Atherton, California

  • GSK Investigational Site

    Culver City, California

  • GSK Investigational Site

    Encino, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Irvine, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Laguna Hills, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Mather, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Orange, California

  • GSK Investigational Site

    Pico Rivera, California

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Salinas, California

  • GSK Investigational Site

    San Bernardino, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

Showing 40 of 932 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.